Business Insider8d
Novartis’ Ianalumab granted FDA orphan designation
Novartis (NVS)’ Ianalumab, for the treatment of primary immune thrombocytopenia, was granted FDA orphan designation, according to a post on the agency’s website. Published first on TheFly ...
The Boston Globe10d
Novartis acquires local cardiovascular drugmaker Anthos for $925 million
Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to close in the ...
pharmaphorum2d
FDA starts review of Lantheus’ generic Lutathera
Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs).
Business Insider8d
Novartis downgraded to Neutral from Buy at UBS
UBS analyst Matthew Weston downgraded Novartis (NVS) to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes the company’s key growth drivers are already ...
MedCity News10d
Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots
Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...
Business Wire10d
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...
Wall Street Journal10d
Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
Novartis NOVN-2.46%decrease; red down pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The ...
pharmaphorum5d
Manufacturing foul-up hits Novartis' radioligand business
Novartis has several ongoing clinical trials using both Pluvicto and Lutathera that will be impacted by its manufacturing issues, according to the company. For Pluvicto that includes a pair of ...
FiercePharma24d
Novartis' first Super Bowl ad aims to 'create a movement' with breast cancer awareness blitz
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s biggest stages. The drugmaker’s first-ever Super Bowl ad is set to ...
STAT10d
Pharmalittle: We’re reading about AI prescribing drugs, a Novartis deal, and more
Top of the morning to you, and a fine one it is, despite the dreary gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we ...
USA Today24d
Hailee Steinfeld's 'bucket list' Super Bowl commercial raises breast cancer awareness
But Steinfeld is gearing up for another arena. Steinfeld is teaming up with pharmaceutical company Novartis to raise awareness about breast cancer with a bold and empowering commercial that will ...
Ad Age24d
Novartis will make its Super Bowl debut with a breast cancer awareness ad
Are you a print subscriber? Activate your account. By Tim Nudd - 19 hours 17 min ago By Amir Farhang - 19 hours 17 min ago By Ashley Joseph - 1 day 17 hours ago By Ad Age Staff - 1 day 17 hours ...